Obermatt
See Similar Stocks →

Natera

NSQ:NTRA · US6323071042
BiotechnologyLarge

360

39
Profit price100
Owner Earnings Yield1
Dividend Yield1
Price/Sales24
EV / Gross Profit28
Price/Book5
Return on Capital42
Cash Return on Capital42
Return on Equity44
EBIT Margin29
Gross Profitability94
Accruals77
Owner Earnings Margin43
Sales growth56
Profit growth9
Reinvestment24
Price momentum58
Debt load60
Refinancing54
Debt Payback1
Liquidity4
Analyst ratings58
Opinion Changes50
Price Target Upside31
Market mood73
Value Creation8/20creating some value
  • Creates more value than its capital costs
  • Owner earnings growing
  • Owner earnings per share growing
  • Reinvests at strong returns
  • Solid earnings base

What this means

Natera clears its cost of capital, but the record is mixed across the five tests. Real value creation, just not yet consistent.

Profile

CountryUSA
IndustryBiotechnology
SizeLarge
TypePublic Company
ExchangeNASDAQGS
Founded2007
Employees4,860
Websitenatera.com
ISINUS6323071042
Last UpdateApr 2, 2026
Indices
NASDAQ (USA)D.J. US Health Care
Themes
Health DiagnosticsFertilityNephrologyGeneticsSoftware DevelopmentGenetic DisorderOncologyBiotechnologyMedical

Description

Natera, Inc. operates as a diagnostics company with proprietary molecular and bioinformatics technology that the company is applying to change the management of disease worldwide. The company’s cell-free DNA, or cfDNA, technology combines its novel…

Analysis

Middle-of-the-road

Natera, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 8/20 on our value-creation score: creating some value.

No flags apply to this company at this time: accounts, balance sheet, and cash quality all pass. A clean bill of health is meaningful, not just the absence of a warning. This analysis describes numbers; it is not investment advice.

360° rank · history

1007550250
34
2026

All-time high

34

Jun 2026

All-time low

34

Jun 2026

Average rank

34

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
24
—
—
—
Price/Earnings
100
—
—
—
Price/Book
5
—
—
—
Dividend Yield
1
—
—
—
Value (overall)
35
—
—
—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Natera with its peers
Myriad Genetics
NSQ:MYGN
12
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kestra Medical Technologies
NSQ:KMTS
21
CountryUSA
IndustryHealth Care Equipment & Supplies
SizeSmall
Full Stock Analysis →
MannKind
NMQ:MNKD
24
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Kenvue
NYQ:KVUE
27
CountryUSA
IndustryPersonal Products
SizeX-Large
Full Stock Analysis →
Caris Life Sciences
NSQ:CAI
93
CountryUSA
IndustryBiotechnology
SizeSmall
Full Stock Analysis →
LifeStance Health
NSQ:LFST
80
CountryUSA
IndustryHealth Care Providers & Services
SizeMedium
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →